Antifungals: Mechanism of action and drug resistance

Advances in Experimental Medicine and Biology

Volumn 892, Issue , 2016, Pages 327-349

  Prasad, Rajendra ^a,b   Shah, Abdul Haseeb ^a   Rawal, Manpreet Kaur ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b AMITY UNIVERSITY HARYANA   (India)

Author keywords

Antifungal agents; Azoles; Combination therapy; Drug efflux; Erg11p; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ALLYLAMINE; ANTIFUNGAL AGENT; ECHINOCANDIN; ERGOSTEROL; MEMBRANE PROTEIN; MFS TRANSPORTER; MORPHOLINE DERIVATIVE; POLYENE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; THIOCARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG; FUNGAL PROTEIN; OXIDOREDUCTASE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; BINDING AFFINITY; BINDING SITE; CANDIDA; CLINICAL EFFECTIVENESS; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; DRUG TRANSPORT; DRUG USE; ERG11P GENE; FUNGAL GENE; FUNGUS ISOLATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANDIDIASIS; CELL MEMBRANE; CELL WALL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; CELL MEMBRANE; CELL WALL; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; ERGOSTEROL; FUNGAL PROTEINS; GENE EXPRESSION; HUMANS; MORPHOLINES; OXIDOREDUCTASES; POLYENES; THIOCARBAMATES;

EID: 84953321231     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-25304-6_14     Document Type: Chapter

References (115)

1. Balashov SV, Park S, Perlin DS (2006) Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50:2058-2063
2. Bills GF, Platas G, Overy DP, Collado J, Fillola A, Jiménez MR et al (2009) Discovery of the parnafungins, antifungal metabolites that inhibit mRNA polyadenylation, from the Fusarium larvarum complex and other Hypocrealean fungi. Mycologia 101:449-472
3. Bink A, Pellens K, Cammue BPA, Thevissen K (2011) Anti-Biofilm Strategies: how to Eradicate Candida Biofilms? Open Mycol J 5:29-38
4. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13
5. Calabrese EC, Castellano S, Santoriello M, Sgherri C, Quartacci MF, Calucci L et al (2013) Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and - resistant strains of Candida albicans. J Antimicrob Chemother 68:1111-1119
6. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV et al (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22:291-321
7. Capobianco JO, Zakula D, Coen ML, Goldman RC (1993) Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. Biochem Biophys Res Commun 190:1037-1044
8. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden Bossche H (2001) Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNAmicroarray. Antimicrob Agents Chemother 45:1660-1670
9. Dean M, Andrey R, Rando A (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166
10. Decottignies A, Grant AM, Nichols JW, De Wet H, McIntosh DB, Goffeau A (1998) ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p. J Biol Chem 273:12612-12622
11. Dhamgaye S, Devaux F, Manoharlal R, Vandeputte P, Shah AH, Singh A et al (2012) In vitro effect of malachite green on Candida albicans involves multiple pathways and transcriptional regulators UPC2 and STP2. Antimicrob Agents Chemother 56:495-506
12. Dhamgaye S, Devaux F, Vandeputte P, Khandelwal NK, Sanglard D,Mukhopadhyay G et al (2014) Molecular mechanisms of action of herbal antifungal alkaloid berberine, in Candida albicans. PLoS One 9:e104554
13. Domínguez JM, Martín JJ (1998) Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother 42:2279-2283
14. Domínguez JM, Kelly VA, Kinsman OS, Marriott MS, Gómez de las Heras F, Martín JJ (1998) Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother 42:2274-2278
15. Espinel-Ingroff A (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol 26:15- 22
16. Espinel-Ingroff A, Canton E, Martin-Mazuelos E, Pemán J (2009) Pharmacotherapy of Candida Infections with Echinocandins. Clin Med Ther 1:889-897
17. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE et al (2012) Gain-of function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 11:1289-1299
18. Fostel JM, Lartey PA (2000) Emerging novel antifungal agents. Drug Discov Today 5:25-32
19. Gallo-Ebert C, Donigan M, Stroke IL, Swanson RN, Manners MT, Francisco J et al (2014) Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor. Antimicrob Agents Chemother 58:258-266
20. Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM (2012) The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis 16:e76-e81
21. Garcia-Effron G, Park S, Perlin DS (2009) Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53:112-122
22. GaurM, Choudhury D, Prasad R (2005) Complete inventory of ABC proteins in human pathogenic yeast, Candida albicans. J Mol Microbiol Biotechnol 9:3-15
23. Gaur M, Puri N, Manoharlal R, Rai V, Mukhopadhayay G, Choudhury D et al (2008) MFS transportome of the human pathogenic yeast Candida albicans. BMC Genomics 9:579
24. Ghannoum MA, Spellberg BJ, Ibrahim AS, Ritchie JA, Currie B, Spitzer ED et al (1994) Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother 38:2029-2033
25. Golin J, Ambudkar SV, May L (2007) The yeast Pdr5p multidrug transporter: how does it recognize so many substrates? Biochem Biophys Res Commun 356:1-5
26. Gow NA, Hube B (2012) Importance of the Candida albicans cell wall during commensalism and infection. Curr Opin Microbiol 15:406-412
27. Gubbins PO, Anaissie E (2006) Overview of antifungal agents. Pharmacy practice news special edition 59-64
28. Gunawardana G, Rasmussen RR, Scherr M, Frost D, Brandt KD, Choi W et al (1997) Corynecandin: a novel antifungal glycolipid from Coryneum modonium. J Antibiot (Tokyo) 50:884-886
29. Harris GH, Shafiee A, Cabello MA, Curotto JE, Genilloud O, Göklen KE et al (1998) Inhibition of fungal sphingolipid biosynthesis by rustmicin, galbonolide B and their new 21-hydroxy analogs. J Antibiot (Tokyo) 51:837-844
30. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J (2010) An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother 54:353-359
31. Heitman J (2011) Microbial pathogens in the fungal kingdom. Fungal Biol Rev 25:48-60
32. Henry KW, Nickels JT, Edlind TD (2000) Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 44:2693-2700
33. Herreros E, Martinez CM, Almela MJ, Marriott MS, De Las Heras FG, Gargallo-Viola D (1998) Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob Agents Chemother 42:2863-2869
34. Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R et al (2008) Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 61:1132-1139
35. Hoot SJ, Smith AR, Brown RP, White TC (2011) An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother 55:940-942
36. Iwamoto T, Tsujii E, Ezaki M, Fujie A, Hashimoto S, Okuhara M et al (1990) FR109615, a new antifungal antibiotic from Streptomyces setonii. Taxonomy, fermentation, isolation, physicochemical properties and biological activity. J Antibiot (Tokyo) 43:1-7
37. Jiang B, Xu D, Allocco J, Parish C, Davison J, Veillette K et al (2008) PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem Biol 15:363-374
38. Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS (2014) Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob Agents Chemother 58:1248-1251
39. Kakeya H, Miyazaki Y, Senda H, Kobayashi T, Seki M, Izumikawa K et al (2008a) Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrob Agents Chemother 52:1868-1870
40. Kakeya H, Miyazaki Y, Senda H, Kobayashi T, Seki M, Izumikawa K et al (2008b) Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob Agents Chemother 52:1871-1872
41. Kaneto R, Chiba H, Agematu H, Shibamoto N, Yoshioka T, Nishida H et al (1993) Mer-WF3010, a new member of the papulacandin family. I. Fermentation, isolation and characterization. J Antibiot (Tokyo) 46:247-250
42. Kantarcioglu AS, Yucel A, Vidotto V (2003) In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp. clinical isolates. J Chemother 15:296-298
43. Karababa M, Coste AT, Rognon B, Bille J, Sanglard D (2004) Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother 48:3064-3079
44. Katiyar SK, Edlind TD (2001) Identification and expression of multidrug resistance related ABC transporter genes in Candida krusei. Med Mycol 39:109-116
45. Kinsman OS, Chalk PA, Jackson HC, Middleton RF, Shuttleworth A, Rudd BA et al (1998) Isolation and characterisation of an antifungal antibiotic (GR135402) with protein synthesis inhibition. J Antibiot (Tokyo) 51:41-49
46. Kitamura A, Someya K, Hata M, Nakajima R, Takemura M (2009) Discovery of a small-molecule inhibitor of fbetag-1,6-glucan synthesis. Antimicrob Agents Chemother 53:670-677
47. Kohli A, Smirti, Mukhopadhyay K, Rattan A, Prasad R (2002) In vitro low-level resistance to azole in Candida albicans is associated with changes in membrane fluidity and asymmetry. Antimicrob Agents Chemother 46:1046-1052
48. Konishi M, Nishio M, Saitoh K, Miyaki T, Oki T, Kawaguchi H (1989) Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot (Tokyo) 42:1749-1755
49. Kusch H, Biswas K, Schwanfelder S, Engelmann S, Rogers PD, HeckerMet al (2004) A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol Genet Genomics 271:554-565
50. Lamb DC, Maspahy S, Kelly DE, Manning NJ, Geber A, Bennett JE et al (1999) Purification, reconstitution, and inhibition of cytochrome P-450 sterol delta22-desaturase from the pathogenic fungus Candida glabrata. Antimicrob Agents Chemother 43:1725-1728
51. Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD (2010) Fungal PDR transporters: phylogeny, topology, motifs and function. Fungal Genet Biol 47:127-142
52. Lemke A, Kiderlen AF, Kayser O (2005) Amphotericin B. Appl Microbiol Biotechnol 68:151-162
53. Lewis RE, Kontoyiannis DP (2001) Rationale for combination antifungal therapy. Pharmacotherapy 21:149S-164S
54. Liu TT, Lee REB, Barker KS, Lee RE,Wei L, Homayouni R et al (2005) Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 49:2226-2236
55. López-Martínez R (2010) Candidosis, a new challenge. Clin Dermatol 28:178-184
56. Mandala SM, Thornton RA, Rosenbach M, Milligan J, Garcia-Calvo M, Bull HG et al (1997) Khafrefungin, a novel inhibitor of sphingolipid synthesis. J Biol Chem 272:32709-32714
57. Mandala SM, Thornton RA,Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG et al (1998) Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem 273:14942-14949
58. Mansfield BE, Oltean HN, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L et al (2010) Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog 6(9):e1001126
59. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W et al (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701-2713
60. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG et al (2010) A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother 54:3578-3583
61. Miceli MH, Bernardo SM, Lee SA (2009) In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 34:326-332
62. Mitsuyama J, Nomura N, Hashimoto K, Yamada E, Nishikawa H, Kaeriyama M et al (2008) In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 52:1318-1324
63. Miyazaki H, Miyazaki Y, Geber A, Parkinson T, Hitchcock C et al (1998) Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother 42:1695-1701
64. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC (1998) Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 42:1819-1830
65. Morio F, Loge C, Besse B, Hennequin C, Le Pape P (2010) Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373-384
66. Munro CA, Winter K, Buchan A, Henry K, Becker JM, Brown AJ et al (2001) Chs1 of Candida albicans is an essential chitin synthase required for synthesis of the septum and for cell integrity. Mol Microbiol 39:1414-1426
67. Nagiec MM, Nagiec EE, Baltisberger JA, Wells GB, Lester RL, Dickson RC (1997) Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. J Biol Chem 272:9809-9817
68. Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y (2009) In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother 15:1-5
69. Ogawa A, Hashida-Okado T, Endo M, Yoshioka H, Tsuruo T, Takesako K et al (1998) Role of ABC transporters in aureobasidin A resistance. Antimicrob Agents Chemother 42:755-761
70. Okada H, Kamiya S, Shiina Y, Suwa H, Nagashima M, Nakajima S et al (1998) BE-31405, a new antifungal antibiotic produced by Penicillium minioluteum. I. Description of producing organism, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 51:1081-1086
71. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT (2005) Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 49:4895-4902
72. Pagant S, Halliday JJ, Kougentakis C, Miller EA (2010) Intragenic suppressing mutations correct the folding and intracellular traffic of misfolded mutants of Yor1p, a eukaryotic drug transporter. J Biol Chem 285:36304-36314
73. Pai MP, Samples ML, Mercier RC, Spilde MN (2008) Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother 52:2367-2376
74. Parish CA, Smith SK, Calati K, Zink D, Wilson K, Roemer T et al (2008) Isolation and structure elucidation of parnafungins, antifungal natural products that inhibit mRNA polyadenylation. J Am Chem Soc 130:7060-7066
75. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E et al (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49:3264-3273
76. Pasrija R, Banerjee D, Prasad R (2007) Structure and function analysis of CaMdr1p, a major facilitator superfamily antifungal efflux transporter protein of Candida albicans: identification of amino acid residues critical for drug/HC transport. Eukaryot Cell 6:443-453
77. Perlin DS (2007) Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121- 130
78. Perlin DS (2011) Current perspectives on echinocandin class drugs. Future Microbiol 6:441-457
79. Petraitis V, Petraitiene R, Kelaher AM, Sarafandi AA, Sein T, Mickiene D et al (2004) Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob Agents Chemother 48:3959-3967
80. Prasad R, Goffeau A (2012) Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu Rev Microbiol 66:39-63
81. Prasad R, Kapoor K (2005) Multidrug resistance in yeast Candida. Int Rev Cytol 242:215-248
82. Prasad R, DeWergifosse P, Goffeau A, Balzi E (1995) Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 27:320-329
83. Prasad T, Hameed S, Manoharlal R, Biswas S, Mukhopadhyay CK, Goswami SK et al (2010) Morphogenic regulator EFG1 affects the drug susceptibilities of pathogenic Candida albicans. FEMS Yeast Res 10:587-596
84. Rodrigues ME, Silva S, Azeredo J, Henriques M (2014) Novel strategies to fight Candida species infection. Crit Rev Microbiol 10:1-13
85. Roemer T, Krysan DJ (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4 pii:a019703
86. Saier MH Jr, Beatty JT, Goffeau A, Harley KT, Heijne WHM, Huang SC et al (1999) The major facilitator superfamily. J Mol Microbiol Biotechnol 1:257-279
87. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J (1999) The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 43:2753-2765
88. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 47:2404-2412
89. Sanglard D, Coste A, Ferrari S (2009) Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 9:1029-1050
90. Sanguinetti M, Posteraro B, La Sorda M, Torelli R, Fiori B, Santangelo R et al (2006) Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect Immun 74:1352-1359
91. Sasse C, Schillig R, Reimund A, Merk J, Morschhäuser J (2012) Inducible and constitutive activation of two polymorphic promoter alleles of the Candida albicans multidrug efflux pump MDR1. Antimicrob Agents Chemother 56:4490-4494
92. Serena C, Fernández-Torres B, Pastor FJ, Trilles L, Lazéra Mdos S, Nolard N et al (2005) In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 49:2994-2996
93. Shapiro RS, Robbins N, Cowen LE (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75:213-267
94. Sharma M, Manoharlal R, Shukla S, Puri N, Prasad T, Ambudkar SV et al (2009) Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother 53:3256-3265
95. Sharma M, Manoharlal R, Puri N, Prasad R (2010) Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in Candida albicans. Biosci Rep 30:391-404
96. Shi W, Chen Z, Chen X, Cao L, Liu P, Sun S (2010) The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Res 10:885-893
97. Shibata T, Takahashi T, Yamada E, Kimura A, Nishikawa H, Hayakawa H et al (2012) T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother 56:5892-5897
98. St Georgiev V (2000) Membrane transporters and antifungal drug resistance. Curr Drug Targets 1:261-284
99. Stephanie SP, Paulsen IT, Saier MH Jr (1998) Major facilitator superfamily. Microbiol Mol Biol Rev 62:1-34
100. Thornewell SJ, Peery RB, Skatrud PL (1997) Cloning and characterization of CneMDR1: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene 201:21-29
101. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E (2010a) In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother 65:271-274
102. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E (2010b) Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 53:208-214
103. Torelli R, Posteraro B, Ferrari S, La Sorda M, Fadda G, Sanglard D et al (2008) The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol 68:186-201
104. Uppuluri P, Nett J, Heitman J, Andes D (2008) Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52:1127-1132
105. Vanden Bossche H, Marichal P, Le Jeune L, Coene MC, Gorrens J, Cools W (1993) Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 37:2101-2105
106. Vandeputte P, Tronchin G, Berge's T, Hennequin C, Chabasse D, Bouchara JP (2007) Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother 51:982-990
107. Vandeputte P, Ferrari S, Coste AT (2012) Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012:713687
108. Verrier PJ, Bird D, Burla B, Dassa E, Forestier C, Geisler M et al (2008) Plant ABC proteins-a unified nomenclature and updated inventory. Trends Plant Sci 13:151-159
109. Wang H, Kong F, Sorrell TC, Wang B, McNicholas P, Pantarat N et al (2009) Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. BMC Microbiol 14:167
110. White TC, Silver PM (2005) Regulation of sterol metabolism in Candida albicans by the UPC2 gene. Biochem Soc Trans 33:1215-1218
111. White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382-402
112. White TC, Holleman S, Dy F, Mirels LF, Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46:1704-1713
113. Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI et al (2015) The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin- Resistant Candida albicans. Antimicrob Agents Chemother 59:1341-1343
114. Young LY, Hull CM, Heitman J (2003) Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother 47:2717-2724
115. Zhang YQ, Gamarra S, Garcia-Effron G, Park S, Perlin DS, Rao R (2010) Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathog 6:e1000939